Back to search
FDAFDA · Food and drugs·Recall number D-0517-2017

Buprenorphine and Naloxone Sublingual Tablets 8 mg/2 mg, 30 count HDPE bottles, Rx Only, Distributed by TEVA PHARMACEUTICALS USA, INC., North Wales, PA 19454, NDC 0093-5721-56

Published March 22, 2017 · Recall initiated: February 7, 2017

Summary

FDA records drug Class II recall D-0517-2017, published March 22, 2017 and initiated February 7, 2017. Recalling firm: Teva Pharmaceuticals USA; Status: Terminated; Reported quantity: 7,628 HDPE bottles (228,840 tablets); Lot: Lot 30227056A; Exp. 03/17. Class II means possible temporary or medically reversible effects, or a remote probability of serious health consequences.

Status when published: Terminated — openFDA updates weekly, so this field may not reflect the current status. Always confirm with the official notice.

What's the hazard

Failed Impurities/Degradation Specifications

What to do

Voluntary: Firm initiated · Letter

Get an email when a new FDA recall like this is published

Free. We only write when there's a new recall that matches. Unsubscribe in one click.

Recall details

Manufacturer
Teva Pharmaceuticals USA
Distributor
Nationwide
Lot
Lot 30227056A; Exp. 03/17
Risk classification
Class II
Area (FDA)
drug
Country
United States

Related recalls

Questions about this recall

Was Buprenorphine and Naloxone Sublingual Tablets 8 mg/2 mg, 30 count HDPE bottles, Rx Only, Distributed by TEVA PHARMACEUTICALS USA, INC., North Wales, PA 19454, NDC 0093-5721-56 recalled?

Yes. FDA published recall D-0517-2017 on March 22, 2017. Reported hazard: Failed Impurities/Degradation Specifications

What should I do if I have this product?

Voluntary: Firm initiated · Letter